The best corporate managers are always one step ahead. Salesforce is the second coming of Amazon.com...
Abiomed: Heartfelt Buy
02/19/2015 8:00 am EST
This featured small-cap recommendation is a leading provider of mechanical circulatory support devices as part of a broader offering of care to heart failure patients, notes Jim Oberweis, Jr., editor of The Oberweis Report.
Abiomed, Inc. (ABMD) develops, manufactures, and markets proprietary products that are designed to enable the heart to rest, heal, and recover by improving blood flow and/or performing the pumping function of the heart.
Their products are used in the cardiac catheterization lab, or cath lab, by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of medical support prophylactically or emergently before, during, or after angioplasty or heart surgery procedures.
Heart recovery is the ideal clinical outcome for patients experiencing heart failure because it restores their quality of life, in addition to it being the most cost-effective solution to the healthcare system for the care of such patients.
The majority of the company’s revenue growth is the market penetration of their Impella family of products and principally their Impella 2.5 product.
The company recently announced that it expects to receive additional FDA Pre-Market Approval (PMA) allowing the company to market the product to very sick patients undergoing cardiac procedures.
In the company’s latest reported third quarter, sales increased approximately 34% to $62.0 million from $46.2 million in the third quarter of last year.
Abiomed reported earnings per share of $0.30 in the latest reported third quarter versus $0.11 in the same quarter of last year. Clients of Oberweis Asset Management own approximately 94,000 shares.
More from MoneyShow.com:
Related Articles on STOCKS
Now about new highs being celebrated, amidst deterioration of a slew of internals: This suggests nei...
Our daily breakout stock ideas are most suitable for aggressive investors seeking ideal entry points...
I understand, my views are not outside the mainstream, but long-term investors should buy Apple shar...